Impact of the COVID-19 Pandemic on HIV Services in Korea : Results from a Cross-Sectional Online Survey
Copyright © 2021 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS..
BACKGROUND: Globally, the coronavirus disease 2019 (COVID-19) pandemic has compromised human immunodeficiency virus (HIV) services. The study aimed to assess the impact of COVID-19 on the access and delivery of HIV care in Korea.
MATERIALS AND METHODS: People living with HIV (PLHIV), people at risk of HIV (PAR) and prescribers of HIV care were recruited through a patient advocacy group, online communities for men who have sex with men (MSM) and a HIV care center for a web-based survey between October 22 and November 26, 2020. The survey compared the frequency of hospital/clinic visits, HIV-related testing, access to antiretroviral therapy (ART) or preventive medications, and experience with telehealth services by PLHIV and PAR between the pre-pandemic and pandemic eras.
RESULTS: One hundred and twelve PLHIV (mean age: 38.5 ± 10.2 years), 174 PAR (mean age: 33.5 ± 8.0 years) and 9 prescribers participated the survey; ≥97% of the PLHIV and PAR were male. A greater proportion of PAR than PLHIV reported a decrease in the frequency of hospital/clinical visits (59.2% vs. 17.0%) and HIV-related testing (50.6% vs. 6.3%) since COVID-19. Among PAR, not engaging or engaging less in high-risk behaviors was the most frequently cited reason (51.1%) for decreased frequency of HIV-related tests. A substantial proportion of PLHIV (12.5%) and PAR (50.0%) experienced interrupted use of ART and HIV preventive medications, respectively. A substantial proportion of PLHIV (35.7%) and PAR (62.5%) were concerned about the long-term accessibility of HIV care, however, >90% had not used any types of telehealth services during the pandemic.
CONCLUSION: Overall, COVID-19 has negatively impacted the access and delivery of HIV services in Korea, especially HIV-related testing for PAR. Our findings highlight the need to develop strategies to mitigate the interrupted HIV care.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Infection & chemotherapy - 53(2021), 4 vom: 31. Dez., Seite 741-752 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Jeong-A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-retroviral agents |
|---|
| Anmerkungen: |
Date Revised 14.01.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3947/ic.2021.0112 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335150667 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335150667 | ||
| 003 | DE-627 | ||
| 005 | 20231225225215.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3947/ic.2021.0112 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335150667 | ||
| 035 | |a (NLM)34979605 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Jeong-A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of the COVID-19 Pandemic on HIV Services in Korea |b Results from a Cross-Sectional Online Survey |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS. | ||
| 520 | |a BACKGROUND: Globally, the coronavirus disease 2019 (COVID-19) pandemic has compromised human immunodeficiency virus (HIV) services. The study aimed to assess the impact of COVID-19 on the access and delivery of HIV care in Korea | ||
| 520 | |a MATERIALS AND METHODS: People living with HIV (PLHIV), people at risk of HIV (PAR) and prescribers of HIV care were recruited through a patient advocacy group, online communities for men who have sex with men (MSM) and a HIV care center for a web-based survey between October 22 and November 26, 2020. The survey compared the frequency of hospital/clinic visits, HIV-related testing, access to antiretroviral therapy (ART) or preventive medications, and experience with telehealth services by PLHIV and PAR between the pre-pandemic and pandemic eras | ||
| 520 | |a RESULTS: One hundred and twelve PLHIV (mean age: 38.5 ± 10.2 years), 174 PAR (mean age: 33.5 ± 8.0 years) and 9 prescribers participated the survey; ≥97% of the PLHIV and PAR were male. A greater proportion of PAR than PLHIV reported a decrease in the frequency of hospital/clinical visits (59.2% vs. 17.0%) and HIV-related testing (50.6% vs. 6.3%) since COVID-19. Among PAR, not engaging or engaging less in high-risk behaviors was the most frequently cited reason (51.1%) for decreased frequency of HIV-related tests. A substantial proportion of PLHIV (12.5%) and PAR (50.0%) experienced interrupted use of ART and HIV preventive medications, respectively. A substantial proportion of PLHIV (35.7%) and PAR (62.5%) were concerned about the long-term accessibility of HIV care, however, >90% had not used any types of telehealth services during the pandemic | ||
| 520 | |a CONCLUSION: Overall, COVID-19 has negatively impacted the access and delivery of HIV services in Korea, especially HIV-related testing for PAR. Our findings highlight the need to develop strategies to mitigate the interrupted HIV care | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-retroviral agents | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a HIV infections | |
| 650 | 4 | |a Pre-exposure prophylaxis | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Kim, Yeni |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Jun Yong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection & chemotherapy |d 2013 |g 53(2021), 4 vom: 31. Dez., Seite 741-752 |w (DE-627)NLM232968403 |x 2093-2340 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2021 |g number:4 |g day:31 |g month:12 |g pages:741-752 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3947/ic.2021.0112 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2021 |e 4 |b 31 |c 12 |h 741-752 | ||